



September 30, 2026

Company name: Fuso Pharmaceutical Industries, Ltd.
Representative: Mikio Toda, President and Representative
Director
(Securities code: 4538, Tokyo Stock
Exchange Prime Market)
Inquiries: Corporate Communication Office, Corporate
Planning Division
(Telephone (main): +81-6-6969-1131)

Notice Concerning Conclusion of Design-Build Contract for Okayama Second Factory

Fuso Pharmaceutical Industries, Ltd. (the “Company”) hereby announces that, pursuant to a resolution of its Board of Directors dated September 30, 2026, it has concluded a design-build contract with Chiyoda X-ONE Engineering Corporation (“CXO”) for the construction of the Okayama Second Factory, as planned under its medium-term management plan “FUSO VISION 2030 Next Stage” (the “Plan”), announced on August 8, 2025. Details are provided below.

1. Overview

The Company considers the stable and continuous supply of essential pharmaceuticals indispensable to medical care to be an important social mission. The existing Okayama Factory (located in Satoshō-cho, Asakuchi-gun, Okayama Prefecture) has, since its establishment in 1985, served as a production base for dialysates, infusions, and injections, underpinning the supply infrastructure for Western Japan.

The Company has decided to enter into a design-build contract with CXO, a company with extensive expertise in the construction of pharmaceutical manufacturing facilities, for the construction of the Okayama Second Factory, which will be equipped with a multi-story automated warehouse, on the premises of the Okayama Factory. This is intended to further strengthen business continuity planning (BCP) and improve production efficiency as outlined in the Plan.

CXO, a member of the Chiyoda Corporation Group, is one of Japan’s leading engineering companies with a strong track record in the life sciences sector. CXO will provide comprehensive engineering services from design through construction, including project management for this large-scale investment.

The establishment of a new production line of powder dialysate at the Okayama Second Factory will expand the Company’s supply capacity for these products and further strengthen its stable supply system. In addition, the Company will transfer the functions of its Daito Factory (located in Daito-shi, Osaka Prefecture), a production base for oral drugs, to the new factory, in order to reorganize and consolidate its domestic production network and upgrade the production with higher-productivity lines as part of its effort to enhance manufacturing efficiency.

Through these initiatives, the Company will continue to pursue the realization of the FUSO VISION, “To become an essential company that sustains society through health care as a manufacturer of basic pharmaceutical products,” contributing further to patients and healthcare in Japan.



Rendering of the Okayama Second Factory

2. Overview of the Okayama Second Factory

Name	Okayama Second Factory
Location	9033 Satomi, Satoshō-cho, Asakuchi-gun, Okayama *Located on the same premises as the Okayama Factory
Building structure	Steel-framed, 5 stories
Building area	Approx. 3,400 m ²
Total floor area	Approx. 8,800 m ²
Total investment	Approx. 14 billion yen (including buildings and production equipment, together with associated expenses)
Date of contract execution	September 30, 2026
Scheduled start of construction	December 2026
Scheduled completion	March 2028
Scheduled start of production	December 2028

3. Impact on financial results

The conclusion of this contract will not result in any changes to the Company's financial result forecasts for the fiscal year ending March 31, 2027, as stated in the Non-consolidated Financial Results for the Fiscal Year Ended March 31, 2026 [Under Japanese GAAP] announced on May 12, 2026.

[Integrated engineering company profile]

Chiyoda X-ONE Engineering Corporation

Established : April 1, 2023 (Original registration: April 3, 1974)
Paid-in capital : 150 million yen (Chiyoda Corporation: 100%)
Representative : Takayuki Naito, Representative Director, President
Head office : 3-13 Moriya-cho, Kanagawa-ku, Yokohama-shi, Kanagawa
Business : Integrated engineering business (including planning, designing, procurement,
activities construction, commissioning, and maintenance) and insurance services (non-
life and life insurance agency services)